Document is current
Any future updates will be listed below
-
Authors
Christensen, M
Sparre-Ulrich, A H
Hartmann, B
Grevstad, U
Rosenkilde, M M
Holst, J J
Vilsbøll, T
Knop, F K
- License Information
-
More Information
Article History
Received: 2 January 2015
Revised: 13 May 2015
Accepted: 12 June 2015
First Online: 31 July 2015
Competing interests
: JJH has served as a consultant or advisor to: Novartis Pharmaceuticals, Novo Nordisk, Merck, Sharp and Dome and Roche. JJH has received fees for speaking from Novo Nordisk, Merck, Sharp and Dome and GSK. TV has received fees for consulting, lecturing and/or being part of an advisory board from: AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, GI Dynamics, Merck Sharp & Dohme, Novo Nordisk, Novartis, Sanofi, Takeda and Zealand Pharma. TV has received research support from Novo Nordisk. FKK has received fees for consulting, lecturing and/or being part of an advisory board from: AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, Gilead Sciences, Merck Sharp & Dohme, Novartis, Novo Nordisk, Ono Pharmaceuticals, Sanofi, Zealand Pharma. FKK has received research support from Sanofi and Novo Nordisk. The remaining authors declare no conflicts of interest.
